Zhejiang Haisen Pharmaceutical Co. Ltd. A
Zhejiang Haisen Pharmaceutical Co., Ltd. engages in the research and development, production, sale, and import and export of pharmaceutical intermediates, active pharmaceutical ingredients, and preparations in China and internationally. The company offers active pharmaceutical ingredients for anti-gastric ulcer, antilipemic agent, antipyretic analgesics, antidepressant, analgesic, cardiovascular,… Read more
Zhejiang Haisen Pharmaceutical Co. Ltd. A (001367) - Total Liabilities
Latest total liabilities as of June 2025: CN¥126.36 Million CNY
Based on the latest financial reports, Zhejiang Haisen Pharmaceutical Co. Ltd. A (001367) has total liabilities worth CN¥126.36 Million CNY as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Zhejiang Haisen Pharmaceutical Co. Ltd. A - Total Liabilities Trend (2021–2024)
This chart illustrates how Zhejiang Haisen Pharmaceutical Co. Ltd. A's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Zhejiang Haisen Pharmaceutical Co. Ltd. A Competitors by Total Liabilities
The table below lists competitors of Zhejiang Haisen Pharmaceutical Co. Ltd. A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Brightcove Inc
NASDAQ:BCOV
|
USA | $115.10 Million |
|
Repro Med Systems Inc
NASDAQ:KRMD
|
USA | $10.64 Million |
|
Tongyang Inc
KO:001525
|
Korea | ₩616.60 Billion |
|
Bin Chuan Enterprise Co Ltd
TWO:1569
|
Taiwan | NT$3.26 Billion |
|
Zhejiang Changhua Auto Parts Co Ltd
SHG:605018
|
China | CN¥678.48 Million |
|
Sylvania Platinum Limited
OTCGREY:SAPLF
|
USA | $36.27 Million |
|
United States Cellular Corporation
NYSE:USM
|
USA | $2.38 Billion |
|
Genfit SA
PINK:GNFTF
|
USA | $164.21 Million |
Liability Composition Analysis (2021–2024)
This chart breaks down Zhejiang Haisen Pharmaceutical Co. Ltd. A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 10.95 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.09 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.08 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Zhejiang Haisen Pharmaceutical Co. Ltd. A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Zhejiang Haisen Pharmaceutical Co. Ltd. A (2021–2024)
The table below shows the annual total liabilities of Zhejiang Haisen Pharmaceutical Co. Ltd. A from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥141.84 Million | +54.82% |
| 2023-12-31 | CN¥91.62 Million | -5.13% |
| 2022-12-31 | CN¥96.57 Million | -16.76% |
| 2021-12-31 | CN¥116.02 Million | -- |